Solstice, an AI-driven marketing agency, has successfully raised $21 million in Series A funding, aimed at enhancing the commercialization processes for pharmaceuticals. This funding round, led by Transformation Capital, brings the company's total funding to around $25 million.
This new investment will facilitate Solstice's expansion into the market, drive product development, and enhance team capabilities in both product and customer-facing roles. The agency is dedicated to streamlining the commercialization of new drugs and medical products, addressing the challenges posed by protracted medical, legal, and regulatory (MLR) review cycles that often delay marketing efforts.
Solstice's innovative platform utilizes clinical data and regulatory documents to create compliant marketing campaigns and communications tailored for healthcare providers and patients. By integrating advanced AI models with expert reviews, Solstice claims to enable clients to launch campaigns significantly faster than traditional agencies—reducing the time from concept to market-ready content to about 10 days and decreasing average MLR review rounds substantially.
Currently, Solstice serves over a dozen pharmaceutical companies, including several leading brands in oncology and immunology. The company's approach not only accelerates the marketing process but also enhances the quality of content produced, allowing clients to compete more effectively in a crowded biopharma landscape. This funding round positions Solstice to further innovate in a sector that has seen little change in its commercialization workflows for decades.